Literature DB >> 33764960

Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019.

Rena Fukunaga, Philippe Glaziou, Jennifer B Harris, Anand Date, Katherine Floyd, Tereza Kasaeva.   

Abstract

Although tuberculosis (TB) is curable and preventable, in 2019, TB remained the leading cause of death from a single infectious agent worldwide and the leading cause of death among persons living with HIV infection (1). The World Health Organization's (WHO's) End TB Strategy set ambitious targets for 2020, including a 20% reduction in TB incidence and a 35% reduction in the number of TB deaths compared with 2015, as well as zero TB-affected households facing catastrophic costs (defined as costs exceeding 20% of annual household income) (2). In addition, during the 2018 United Nations High-Level Meeting on TB (UNHLM-TB), all member states committed to setting 2018-2022 targets that included provision of TB treatment to 40 million persons and TB preventive treatment (TPT) to 30 million persons, including 6 million persons living with HIV infection and 24 million household contacts of patients with confirmed TB (4 million aged <5 years and 20 million aged ≥5 years) (3,4). Annual data reported to WHO by 215 countries and territories, supplemented by surveys assessing TB prevalence and patient costs in some countries, were used to estimate TB incidence, the number of persons accessing TB curative and preventive treatment, and the percentage of TB-affected households facing catastrophic costs (1). Globally, TB illness developed in an estimated 10 million persons in 2019, representing a decline in incidence of 2.3% from 2018 and 9% since 2015. An estimated 1.4 million TB-related deaths occurred, a decline of 7% from 2018 and 14% since 2015. Although progress has been made, the world is not on track to achieve the 2020 End TB Strategy incidence and mortality targets (1). Efforts to expand access to TB curative and preventive treatment need to be substantially amplified for UNHLM-TB 2022 targets to be met.

Entities:  

Mesh:

Year:  2021        PMID: 33764960      PMCID: PMC7993552          DOI: 10.15585/mmwr.mm7012a4

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  1 in total

1.  Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study.

Authors:  Alexandra B Hogan; Britta L Jewell; Ellie Sherrard-Smith; Juan F Vesga; Oliver J Watson; Charles Whittaker; Arran Hamlet; Jennifer A Smith; Peter Winskill; Robert Verity; Marc Baguelin; John A Lees; Lilith K Whittles; Kylie E C Ainslie; Samir Bhatt; Adhiratha Boonyasiri; Nicholas F Brazeau; Lorenzo Cattarino; Laura V Cooper; Helen Coupland; Gina Cuomo-Dannenburg; Amy Dighe; Bimandra A Djaafara; Christl A Donnelly; Jeff W Eaton; Sabine L van Elsland; Richard G FitzJohn; Han Fu; Katy A M Gaythorpe; William Green; David J Haw; Sarah Hayes; Wes Hinsley; Natsuko Imai; Daniel J Laydon; Tara D Mangal; Thomas A Mellan; Swapnil Mishra; Gemma Nedjati-Gilani; Kris V Parag; Hayley A Thompson; H Juliette T Unwin; Michaela A C Vollmer; Caroline E Walters; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; Neil M Ferguson; Lucy C Okell; Thomas S Churcher; Nimalan Arinaminpathy; Azra C Ghani; Patrick G T Walker; Timothy B Hallett
Journal:  Lancet Glob Health       Date:  2020-07-13       Impact factor: 26.763

  1 in total
  15 in total

1.  The Microbiota of Human Lung of Pulmonary Tuberculosis and the Alteration Caused by Anti-tuberculosis Drugs.

Authors:  Meng Zhang; Li Shen; Xia Zhou; Huidong Chen
Journal:  Curr Microbiol       Date:  2022-09-19       Impact factor: 2.343

2.  Recurrent Pneumonia With Tuberculosis and Candida Co-infection Diagnosed by Metagenomic Next-Generation Sequencing: A Case Report and Literature Review.

Authors:  Ning Ma; Mei Chen; Jingyi Ding; Fang Wang; Jingbo Jin; Sitong Fan; Jiajia Chen
Journal:  Front Med (Lausanne)       Date:  2022-04-08

3.  Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.

Authors:  Bibie N Said; Scott K Heysell; Getnet Yimer; Rob E Aarnoutse; Gibson S Kibiki; Stellah Mpagama; Peter M Mbelele
Journal:  Int J Mycobacteriol       Date:  2021 Oct-Dec

4.  Misdiagnosis of Budd Chiari syndrome, a case report from Afghanistan.

Authors:  Fardeen Baray; Mohammad Behroz Noori; Mohammad Maroof Aram; Hidayatullah Hamidi
Journal:  Ann Med Surg (Lond)       Date:  2022-01-01

5.  Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.

Authors:  Arnaud Iradukunda; Gabin-Pacifique Ndayishimiye; Darlene Sinarinzi; Emmanuel Nene Odjidja; Nestor Ntakaburimvo; Innocent Nshimirimana; Cheilla Izere
Journal:  BMC Public Health       Date:  2021-11-23       Impact factor: 3.295

6.  Tuberculosis contact tracing yield and associated factors in Uganda.

Authors:  Joseph Baruch Baluku; Martin Nabwana; Muttamba Winters; Felix Bongomin
Journal:  BMC Pulm Med       Date:  2022-02-16       Impact factor: 3.317

7.  Chest X-ray findings in drug-sensitive and drug-resistant pulmonary tuberculosis patients in Uganda.

Authors:  Anthony Oriekot; Senai Goitom Sereke; Felix Bongomin; Samuel Bugeza; Zeridah Muyinda
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-03-25

Review 8.  Lessons Learned During the COVID-19 Pandemic to Strengthen TB Infection Control: A Rapid Review.

Authors:  Helena J Chapman; Bienvenido A Veras-Estévez
Journal:  Glob Health Sci Pract       Date:  2021-12-21

9.  Estimating the population at high risk for tuberculosis through household exposure in high-incidence countries: a model-based analysis.

Authors:  Jennifer M Ross; Yongquan Xie; Yaqi Wang; James K Collins; Cody Horst; Jessie B Doody; Paulina Lindstedt; Jorge R Ledesma; Adrienne E Shapiro; Prof Simon I Hay; Hmwe H Kyu; Abraham D Flaxman
Journal:  EClinicalMedicine       Date:  2021-11-21

10.  Establishing targets for advanced HIV disease: A call to action.

Authors:  David B Meya; Lillian Tugume; Vennie Nabitaka; Proscovia Namuwenge; Sam Phiri; Rita Oladele; Bilkisu Jibrin; Mojisola Mobolaji-Bello; Cecilia Kanyama; Werner Maokola; Sayoki Mfinanga; Cordelia Katureebe; Ikechukwu Amamilo; Brian Ngwatu; Joseph N Jarvis; Thomas S Harrison; Amir Shroufi; Radha Rajasingham; David Boulware; Nelesh P Govender; Angela Loyse
Journal:  South Afr J HIV Med       Date:  2021-08-10       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.